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Background: Drug-eluting stents (DESs) have been demonstrated to reduce the rate of restenosis and the need for repeat revascularization in de 
novo native coronary artery diseases. However, their clinical value in treating saphenous vein graft (SVG) lesions remains controversial. We therefore 
performed a meta-analysis based on all currently available clinical trials to compare DESs with bare metal stents (BMSs) for SVG intervention.
Methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and Internet sources for clinical studies comparing 
outcomes between DES and BMS among patients undergoing SVG intervention between January 2001 and September 2009. We extracted variables 
related to the study design, setting, participants, and clinical endpoints. Pooled estimates for odds ratios (OR) were computed according to random-
effect methods. 
Results: A total of 22 studies (2 randomized trials and 20 non-randomized comparisons) were included in this meta-analysis, involving 4,516 
patients (2060 in the DES group and 2456 in the BMS group) undergoing percutaneous coronary intervention (PCI) of SVG lesions. All patients 
were followed up for a mean of 6-35 months. Compared to the BMS, DES significantly reduced all-cause mortality (8.3% vs 12.9%; OR 0.66, 95% 
confidence interval [CI] 0.51 to 0.88; p = 0.004) and target vessel revascularization (TVR) (13.2% vs 19.4%; OR 0.58, 95% CI 0.43 to 0.77; p 
< 0.001). There were no significant differences between patients treated with DESs and those with BMSs with respect to the risk of non-fatal 
myocardial infarction (4.3% vs 5.8%; OR 0.77, 95% CI 0.51 to 1.16; p = 0.21) or stent thrombosis (6.0% vs 11.5%; OR 0.48, 95% CI 0.19 to 1.26; 
p = 0.14). The composite of all-cause death, myocardial infarction and TVR was significantly reduced in the DES group in comparison with the BMS 
group (20.0% vs 27.2%; OR 0.58, 95% CI 0.44 to 0.76; p < 0.001).
Conclusions: This meta-analysis of currently available data favored DESs for patients undergoing PCI of diseased SVGs. Results from large-scale 
randomized trials are still needed to definitely establish the role of DES implantation for SVG interventional treatment.
